Emami Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The filing demonstrates the company's adherence to mandatory compliance procedures for the quarter ended 31st March, 2026.

Regulatory Filing Details

The compliance certificate was filed on 6th April, 2026, with both major Indian stock exchanges. Company Secretary and Compliance Officer Ravi Varma signed the submission on behalf of Emami Limited.

Exchange Submissions

The certificate was simultaneously submitted to both premier Indian stock exchanges where Emami's shares are listed.

Registrar Confirmation

Maheshwari Datamatics Pvt. Ltd., serving as Emami's registrar and share transfer agent, provided the compliance certificate dated 2nd April, 2026. The registrar confirmed completion of essential dematerialization processes for the period 1st January, 2026 to 31st March, 2026.

Key confirmations from the registrar included:

• Submission of Demat Transfer Register to depositories and stock exchanges
• Proper destruction and cancellation of physical securities received from depository participants
• Completion of all processes within stipulated regulatory timeframes

Compliance Framework

The filing falls under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly compliance certificates from listed companies. This regulation ensures proper handling of dematerialized securities and maintains transparency in the depository system.

The certificate and related documentation are also available on Emami's corporate website at www.emamiltd.in , providing stakeholders with easy access to compliance information.

Emami Limited has executed a definitive agreement on April 1, 2026, to acquire the remaining 73.5% stake in Axiom Ayurveda Private Limited for an aggregate consideration not exceeding ₹200.00 crores. The transaction, approved by the Board of Directors, marks the company's formal entry into the fast-growing beverage sector through the Alofrut brand.

Definitive Agreement and Phased Completion

Following the execution of the definitive agreement, the acquisition is expected to be completed in a phased manner over the next three months, in accordance with the terms of the agreement and applicable regulatory requirements. In the first tranche, Emami acquired approximately 36.7% additional stake, building upon its existing 26.5% holding in Axiom Ayurveda.

Strategic Leadership Appointments

As Axiom enters its next phase of growth under Emami's leadership, the company has onboarded Harkirat Bedi as the Chief Executive Officer of Axiom Ayurveda Private Limited. Bedi, formerly Vice President & Business Head at Dabur Nepal, is expected to strengthen the leadership team and accelerate expansion in the health and wellness beverage segment.

Axiom's Business Portfolio and Market Position

Axiom's portfolio includes beverage products under the brand "AloFrut", health juices under "Axiom Jeevan Ras", and beauty products under "Mukti Gold". AloFrut juices feature aloe vera pulp as a healthy fusion of aloe vera and fruit blends, available in multiple unique flavours with strong market presence across General Trade and Government Institutions.

Management Commentary on Strategic Vision

Harsha Vardhan Agarwal, Vice Chairman & MD of Emami Limited, stated that the growth strategy centers on building presence in emerging, high-opportunity categories aligning with evolving consumer preferences in health and wellness. The partnership with Axiom over the past two and half years has provided valuable insights and strengthened conviction in this segment.

Rishabh Gupta, Founder of Axiom Ayurveda Private Limited, emphasized that consumers are increasingly moving away from carbonated beverages toward healthier alternatives without compromising taste. He expressed confidence that Emami is the right partner to take Axiom into its next growth phase with deep industry expertise and strong capabilities.

Financial Performance and Market Outlook

Axiom Ayurveda is described as a profitable and growing company, expected to achieve a topline of around ₹180.00 crores in FY26. The acquisition aligns with Emami's strategy of leveraging multiple growth levers through strategic investments in new-age, synergistic segments that complement core businesses.